Alzheimer's Disease Cooperative Study

Last updated

The Alzheimer's Disease Cooperative Study (ADCS) was founded at University of California San Diego in 1991 and coordinates clinical trials of candidate treatments for Alzheimer's disease.

It is funded by the National Institutes of Health as well as companies that develop drugs. The center has coordinated important clinical trials on AD drugs like solanezumab. [1]

History

As of 2008, 75 research sites in the United States and Canada were part of the consortium. Leon Thal served as director until February 2007, when he died; Paul Aisen was recruited to succeed him.

In 2006, the NIH awarded $52 million to ADCS to fund 6 years of further clinical trials. [2]

In 2013 Eli Lilly committed to spending $76.6 million on clinical trials through the center. [3]

Aisen left UCSD in 2015 because he was unhappy with the level of support that UCSD was providing him and due to USC's offer. [4] UCSD and USC ended up in litigation over control of the ADCS and its research data, which at that time involved six ongoing clinical trials and data collected on thousands of clinical trial subjects. [5] [6] Part of the dispute arose because Aisen's lab had uploaded the data from the ADCS onto Amazon Cloud servers and would not give the passwords to UCSD officials. [1] [7] [8] Some aspects of data management were temporarily settled in 2016; [9] as of 2017 the litigation was ongoing. [10] [11] The lawsuit was settled in 2019. [12]

Related Research Articles

<span class="mw-page-title-main">University of California, San Diego</span> Public research university in San Diego, California

The University of California, San Diego is a public land-grant research university in San Diego, California. Established in 1960 near the pre-existing Scripps Institution of Oceanography, UC San Diego is the southernmost of the ten campuses of the University of California, and offers over 200 undergraduate and graduate degree programs, enrolling 33,096 undergraduate and 9,872 graduate students. The university occupies 2,178 acres (881 ha) near the coast of the Pacific Ocean, with the main campus resting on approximately 1,152 acres (466 ha).

<span class="mw-page-title-main">Scripps Research</span> Nonprofit American medical research institute

Scripps Research is a nonprofit American medical research facility that focuses on research and education in the biomedical sciences. Headquartered in San Diego, California, the institute has over 170 laboratories employing 2,100 scientists, technicians, graduate students, and administrative and other staff.

The California Institute for Regenerative Medicine (CIRM) is a state agency that supports research and education in the fields of stem cell and gene therapies. It was created in 2004 after 59% of California voters approved California Proposition 71: the Research and Cures Initiative, which allocated $3 billion to fund stem cell research in California. In 2020 voters approved Proposition 14 that allocated additional funds to CIRM.

The Keck School of Medicine of the University of Southern California teaches and trains physicians, biomedical scientists and other healthcare professionals, conducts medical research, and treats patients. Founded in 1885, it is the second oldest medical school in California after the UCSF School of Medicine.

UC San Diego Health is the academic health system of the University of California, San Diego in San Diego, California. It is the only academic health system serving San Diego and has one of three adult Level I trauma centers in the region. In operation since 1966, it comprises three major hospitals: UC San Diego Medical Center in Hillcrest, Jacobs Medical Center in La Jolla, and UC San Diego Health East Campus Medical Center in East County. The La Jolla campus also includes the Moores Cancer Center, Shiley Eye Institute, Sulpizio Cardiovascular Center, and Koman Family Outpatient Pavilion, and the health system also includes several outpatient sites located throughout San Diego County. UC San Diego Health works closely with the university's School of Medicine and Skaggs School of Pharmacy to provide training to medical and pharmacy students and advanced clinical care to patients.

<span class="mw-page-title-main">Beta-secretase 1</span> Enzyme

Beta-secretase 1, also known as beta-site amyloid precursor protein cleaving enzyme 1, beta-site APP cleaving enzyme 1 (BACE1), membrane-associated aspartic protease 2, memapsin-2, aspartyl protease 2, and ASP2, is an enzyme that in humans is encoded by the BACE1 gene. Expression of BACE1 is observed mainly in neurons and oligodendrocytes.

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

<span class="mw-page-title-main">University of California, San Diego School of Medicine</span> Medical school of UC San Diego

The University of California, San Diego School of Medicine is the graduate medical school of the University of California, San Diego, a public land-grant research university in La Jolla, California. It was the third medical school in the University of California system, after those established at UCSF and UCLA, and is the only medical school in the San Diego metropolitan area. It is closely affiliated with the medical centers that are part of UC San Diego Health.

<span class="mw-page-title-main">Sanford Burnham Prebys Medical Discovery Institute</span> Non-profit medical research institute

Sanford Burnham Prebys is a 501(c)(3) non-profit medical research institute focusing on basic and translational research, with major research programs in cancer, neurodegeneration, diabetes, infectious, inflammatory, and childhood diseases. The institute also specializes in stem cell research and drug discovery technologies.

<span class="mw-page-title-main">Amylin Pharmaceuticals</span> Biopharmaceutical company

Amylin Pharmaceuticals, Inc. is a biopharmaceutical founded in 1987 that was based in San Diego, California. The company was engaged in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. Amylin produced three drugs: Symlin, Byetta (exenatide) and Bydureon.

<span class="mw-page-title-main">Ivor Royston</span> Researcher

Ivor Royston is an American oncologist, researcher, scientist, entrepreneur and venture capitalist, recognized for his efforts to develop treatments for multiple disease targets and to fund biotechnology companies with promising science, technology or medicines. He speaks regularly at healthcare conferences and symposia throughout the United States, Europe and Asia.

Solanezumab is a monoclonal antibody being investigated by Eli Lilly as a neuroprotector for patients with Alzheimer's disease. The drug originally attracted extensive media coverage proclaiming it a breakthrough, but it has failed to show promise in Phase III trials.

Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multisite study that aims to improve clinical trials for the prevention and treatment of Alzheimer's disease (AD). This cooperative study combines expertise and funding from the private and public sector to study subjects with AD, as well as those who may develop AD and controls with no signs of cognitive impairment. Researchers at 63 sites in the US and Canada track the progression of AD in the human brain with neuroimaging, biochemical, and genetic biological markers. This knowledge helps to find better clinical trials for the prevention and treatment of AD. ADNI has made a global impact, firstly by developing a set of standardized protocols to allow the comparison of results from multiple centers, and secondly by its data-sharing policy which makes available all at the data without embargo to qualified researchers worldwide. To date, over 1000 scientific publications have used ADNI data. A number of other initiatives related to AD and other diseases have been designed and implemented using ADNI as a model. ADNI has been running since 2004 and is currently funded until 2021.

Anders Martin Dale is a prominent neuroscientist and professor of radiology, neurosciences, psychiatry, and cognitive science at the University of California, San Diego (UCSD), and is one of the world's leading developers of sophisticated computational neuroimaging techniques. He is the founding Director of the Center for Multimodal Imaging Genetics (CMIG) at UCSD.

<span class="mw-page-title-main">Don W. Cleveland</span> American cancer biologist and neurobiologist

Don W. Cleveland is an American cancer biologist and neurobiologist.

<span class="mw-page-title-main">UC San Diego Medical Center, Hillcrest</span> Hospital in California, United States

The UC San Diego Medical Center, Hillcrest is one of three medical centers of UC San Diego Health and is a teaching hospital for the University of California San Diego School of Medicine.

Steven M. Paul is an American neuroscientist and pharmaceutical executive. Paul was the former CEO, president, and chairman of Karuna Therapeutics.

Paul Stephen Aisen is an American physician and medical researcher. He started his career as a rheumatologist and then made Alzheimer's disease his focus. As of 2015 he was on the faculty of the Keck School of Medicine of USC and his offices were in San Diego.

Cheryl Ann Marie Anderson is an American epidemiologist. Anderson is a professor at and founding Dean of the University of California San Diego Herbert Wertheim School of Public Health and Human Longevity Science. Anderson's research focus is on nutrition and chronic disease prevention in under-served human populations.

Howard H Feldman is a professor of neurosciences at the University of California, San Diego (UCSD). He was appointed director of the Alzheimer's Disease Cooperative Study (ADCS) in April 2016. Prior to joining UCSD, he served as the Executive Associate Dean for Research, Faculty of Medicine, University of British Columbia (UBC) and was the director of the Alzheimer's and Related Disorders Clinic at UBC.

References

  1. 1 2 Garde, Damian (August 5, 2015). "Judge orders a halt to Alzheimer's spat as Eli Lilly chooses sides in dispute". FierceBiotech.
  2. ↑ "Paul Aisen, MD, Joins Faculty of UCSD and is Appointed New Director of the Alzheimer's Disease Cooperative Study". Journal of Investigative Medicine. 56 (1): 3. January 2008. doi:10.1097/01.JIM.0000308082.54350.ba.
  3. ↑ Terry, Mark (July 22, 2015). "Eli Lilly Increases San Diego R&D Space by 140%, Staff by 70%". BioSpace via PharmaLive.
  4. ↑ Fikes, Bradley J. (5 July 2015). "UC San Diego sues USC and scientist, alleging conspiracy to take funding, data". Los Angeles Times.
  5. ↑ Check Hayden, Erika (16 July 2015). "Alzheimer's data lawsuit is sign of growing tensions". Nature. pp. 265–265. doi:10.1038/nature.2015.17932.
  6. ↑ Basken, Paul (23 July 2015). "Grant Dispute Throws an Unwritten Rule of Academic Poaching Out the Window". The Chronicle of Higher Education.
  7. ↑ Fikes, Bradley J. (2 August 2015). "Next steps for scientist in eye of UCSD-USC Alzheimer's spat". San Diego Tribune.
  8. ↑ Wang, Shirley S.; Loftus, Peter (14 October 2015). "Alzheimer's Research Effort Is Ensnared in Legal Dispute". Wall Street Journal.
  9. ↑ Potter, Matt (January 11, 2016). "Deal gives UCSD "read only" rights to Alzheimer's data". San Diego Reader.
  10. ↑ "Case 3:15-cv-01766: The Regents of the University of California v. Aisen et al (3:15-cv-01766), California Southern District Court". PacerMonitor. Retrieved 15 June 2017.
  11. ↑ "Case 8:17-cv-00721: The Regents of the University of California v. Aisen et al (8:17-cv-00721), Maryland District Court". PacerMonitor. Retrieved 15 June 2017.
  12. ↑ "USC pays UCSD $50M, and gives the school an apology, for raiding its Alzheimer's program". San Diego Union-Tribune. 2019-07-04. Retrieved 2022-09-14.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.